Entremed Shares Surge as Cancer Drug Gets FDA Nod

Analyst upgrade lifts eBay; Riverstone sinks on profit outlook; plus more of today's stocks in the news

Shares of Entremed (ENMD ) rose after the company said its drug candidate Endostatin received orphan drug status from FDA for treatment of patients with metastatic melanoma.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.